Showing 6901-6910 of 10618 results for "".
- Pulmonary Hyalinizing Granuloma and Diagnostic Pitfallshttps://reachmd.com/news/pulmonary-hyalinizing-granuloma-and-diagnostic-pitfalls/2486674/Key Takeaways Incidentally detected pulmonary nodules in a 71-year-old man were described as mimicking metastatic disease on imaging. Surgical pathology identified fibrocollagenous nodules with perivascular inflammatory infiltrates, and immunohistochem
- GBM AGILE Phase II/III Bayesian Randomized Platform Trialhttps://reachmd.com/news/gbm-agile-phase-iiiii-bayesian-randomized-platform-trial/2486655/Key Takeaways In GBM AGILE, regorafenib did not improve overall survival versus control in either newly diagnosed unmethylated or recurrent glioblastoma and enrollment stopped early for limited efficacy. The trial used a phase II/III Bayesian adaptive
- AI Immune Profiling on Histopathology Slides in Rectal Cancerhttps://reachmd.com/news/ai-immune-profiling-on-histopathology-slides-in-rectal-cancer/2486667/Key Takeaways TIL positivity was associated with longer disease-free and overall survival, while TAM positivity was associated with shorter disease-free survival in the main cohort. Similar directional patterns were described across the additional coho
- Primary Nonresponse to Biologic Therapy in Spondyloarthropathyhttps://reachmd.com/news/primary-nonresponse-to-biologic-therapy-in-spondyloarthropathy/2486666/Key Takeaways Primary nonresponse was reported in 15.3% of the 261-patient cohort. In regression analysis, arthritis at diagnosis was the baseline feature associated with higher odds of primary nonresponse. Nonresponders were described as diff
- Bedtime Sublingual Cyclobenzaprine in Fibromyalgia: Phase 3 Trial Readouthttps://reachmd.com/news/bedtime-sublingual-cyclobenzaprine-in-fibromyalgia-phase-3-trial-readout/2486669/Key Takeaways This randomized, double-blind, placebo-controlled trial evaluated once-nightly sublingual cyclobenzaprine with a 2 week 2.8 mg lead-in followed by 12 weeks of 5.6 mg dosing. TNX-102 SL was associated with greater improvement than placebo
- Roche WSI Validation Shows Comparable Primary Diagnosis Performancehttps://reachmd.com/news/roche-wsi-validation-shows-comparable-primary-diagnosis-performance/2486645/Two studies evaluated the Roche Digital Pathology Dx system for primary surgical pathology diagnosis: a precision (repeatability/reproducibility) study and an accuracy (method-comparis
- Ultrasound Technologies Expand Role in Noninvasive Facial Rejuvenationhttps://reachmd.com/news/ultrasound-technologies-expand-role-in-noninvasive-facial-rejuvenation/2486640/Ultrasound-based energy devices continue to play an expanding role in noninvasive facial and neck rejuvenation, according to a recent review published online in Facial Plastic Surgery. The authors examine the evolution of high-intensity focused ultrasound (HIFU) into newer technologies s
- External Suturing Technique May Enhance Back Contouring After Weight Losshttps://reachmd.com/news/external-suturing-technique-may-enhance-back-contouring-after-weight-loss/2486607/A recent case series published in Plastic and Reconstructive Surgery–Global Open describes the use of external quilting sutures, or a “hemostatic net,” as an adjunct technique for lower back contouring in patients following massive weight loss. The report included 8 patients who u
- Interim IIT Data Explore Sculptra, Restylane for Menopause, Weight Loss–Related Aesthetic Changeshttps://reachmd.com/news/interim-iit-data-explore-sculptra-restylane-for-menopause-weight-lossrelated-aesthetic-changes/2486595/Interim findings from 2 ongoing investigator-initiated trials supported by Galderma suggest potential roles for Sculptra and the Restylane portfolio in treating aesthetic changes associated with menopause and medication-driven weight loss. In one interim analysis led by Sabrina Fabi, MD, 2
- Childhood Vaccination Coverage At 24 Months Held Steady, With Gapshttps://reachmd.com/news/childhood-vaccination-coverage-at-24-months-held-steady-with-gaps/2486589/Key Takeaways: Most routine coverage at age 24 months among children born in 2021 and 2022 was similar to 2019 and 2020 levels, with declines reported for selected vaccines. Coverage varied by eligibility status, race and ethnicity, poverty status, urb